Hossein A. Ghanbari is a co-founder of Panacea Pharmaceuticals and now serves as its CEO, President, Chief Scientific Officer, and Chairman of the Board. The Company has three drug candidates for cancer (immunotherapy), one of which is currently in Phase 1 clinical trials, and another candidate for treating neural damage (treatment of chemotherapy-induced cognitive impairment). Panacea has developed diagnostic tests for prostate cancer (PC Detect®), breast cancer (BC DetectSM), lung cancer (LC Detect®), and colorectal cancer (CC DetectSM). LC Detect was selected as one of 2007’s Top 10 Medical Breakthroughs by Time magazine. Panacea also has a late-stage pre-clinical cancer imaging program to complete its integrated cancer management approach.
Dr. Ghanbari began his career in the pharmaceutical industry at Abbott Laboratories in Chicago, Ill., where he developed several pharmaceuticals and the first ever commercialized diagnostic test for Alzheimer's Disease (AD). He was part of the New Drug Application (NDA) team for Leupron, the very successful prostate cancer drug, as well as for Survanta, the current drug of choice for preventing and treating respiratory distress syndrome in premature infants. He directed the Analytical sections of the Investigational New Drug (IND) application for an antibody-based antiviral drug, and was a member of Abbott's Technical Advisory Board. Dr. Ghanbari was inducted into the prestigious honorary organization, the Volwiler Society, established by Abbott to recognize the company’s most distinguished and accomplished scientists. After nearly a decade with Abbott, Dr. Ghanbari left to form Molecular Geriatrics Corporation, (a biopharma company focused on developing drugs for neurodegenerative diseases) and served as its Senior Vice-President for R&D. Subsequently, Dr. Ghanbari was instrumental in establishing Nymox Pharmaceutical Corporation (NASDAQ: NYMX), and served as Senior Vice-President for R&D and Strategic Planning as well as a Director on its board. While with Nymox, he developed the first commercially available cerebral spinal fluid- and urine-based diagnostics tests for Alzheimer’s Disease (AD), and identified opportunities for complementary technologies that Nymox in-licensed, which together established the company’s international presence as a leader in AD diagnostics and therapeutics.
Prior to entering private industry, Dr. Ghanbari held professorships at Pennsylvania State University, University of Florida, and Arya-Mehr University of Technology (now Sharif University). He was also on the academic staff of The George Washington University School of Medicine and Health Sciences as an Adjunct Professor. He currently serves as a Board member of the Gastric Cancer Foundation. Dr. Ghanbari received his bachelor of sciences degree, with distinction, from the American University in Beirut, and his master’s and doctorate degrees in Biochemistry from Pennsylvania State University. He has authored over 70 peer reviewed publications, and is an inventor on nearly 100 patents and patent applications worldwide.
Tom Ricks has been a member of the Panacea Board of Directors since December, 2015. Mr. Ricks currently serves as Chief Investment Officer of H&S Ventures LLC, a private investment firm. Prior to taking this position with H&S Ventures in May 2001, he was Chief Executive Officer of The University of Texas Investment Management Company from March 1996 until May 2001. Mr. Ricks also served as Vice Chancellor for Asset Management for The University of Texas System from August 1992 through February 1996 and as Executive Director of Finance and Private Investments from 1988 to 1992. Mr. Ricks received a B.A. in Economics from Trinity College, an M.B.A. from the University of Chicago. He has been a director of Newfield Exploration Company (NYSE:NFX) since 1992 and is Chairman of its Audit Committee. He is a former director of BDM International, DTM Corporation, LifeCell Corporation and Argus Pharmaceuticals. Mr. Ricks also serves on the Investment Committee of the University of California Foundation – Irvine and previously served on the board of the Ocean Institute.
Mehdi Hatamian received his B.S. degree in Electrical Engineering from Sharif University of Technology in 1977, and M.S. and Ph.D. degrees in Electrical Engineering from the University of Michigan in Ann Arbor, in 1978 and 1982 respectively.
From 1978 to 1982, he worked for NASA’s Space Shuttle program, developing hardware and software designs to support in-flight biomedical experiments. From 1982 to 1991, he was a member of the Visual Communications Research and the VLSI Systems Research departments of Bell Laboratories, where he was named Distinguished Member of the Technical Staff in 1988. From 1991 to 1996, he was Vice President of Technology at Silicon Design Experts (SDE), Inc., a company he co-founded. SDE was acquired by Level One Corp. which was later acquired by Intel Corp.
From Aug. 1996 to Feb. 2016 he was with Broadcom Corporation where his most recent position was Senior VP Engineering. Following the acquisition of Broadcom Corp. by AVAGO Technologies, the combined company was named Broadcom Limited where Dr. Hatamian served as a Fellow and Chief Scientist - Central Engineering from Feb. 2016 to Aug. 2016. Dr. Hatamian’s areas of expertise and interest are high-speed VLSI signal processing, full-custom and low power circuit and architecture design, image processing and compression, adaptive filtering, Ethernet transceiver design, high-density and high-speed CMOS design, high temperature superconductors, and biomedical electronics. He has published 50 papers in his areas of expertise and holds 97 issued patents with several patents pending.
He is a Fellow member of the Institute of Electrical and Electronics Engineers (IEEE). He received his Fellow award for his contribution to the design of high-performance digital signal processors. Dr. Hatamian received the “#1 Patent Holder” award from Broadcom Corp. for 2005-06 and 2006-07, and the Broadcom Fellow award in 2011. He received the University of Michigan’s ECE Division Alumni Merit Award for 2008. He served on the Engineering Advisory Council of the University of Michigan from 2006 to 2012. Dr. Hatamian has been elected to the National Academy of Engineering, class of 2016, for contributions to the development of integrated circuits for video, communications, and digital signal processing. He has participated in numerous national and international conferences and other professional activities in his field as keynote speaker, organizer, session chair, panelist, invited lecturer, and moderator. He is on the board of directors of Panacea Pharmaceuticals, Inc. and PharmacoKinesis, Inc.
Mark Lee Ford leads business turnarounds of companies in industries such as financial services and consumer products. Based in Tokyo and Hong Kong, he also educates young entrepreneurs in the region by serving as a business school professor. Dr. Ford's scientific interests include fluid mechanics and oncology. He received his BSc degree in Astrophysics from Trinity College, University of Toronto, MS and Ph.D. degrees in Aerospace Engineering from Boston University, and MBA degree from Duke University.
Eiichi Ida was born in 1951 in Tokyo and graduated from Keio University, B.Ec., in 1972. He worked at The Mitsubishi Bank, Ltd. (The Bank of Tokyo Mitsubishi UFJ Ltd.) prior to joining his family business, Ida Building Co., Ltd. (founded in 1886) running the lease, investment and management of properties. He has been the President and CEO of Ida Building Co., Ltd. and its group companies since 1979 and the director of several companies in Japan, Great Britain, and U.S.A. He is an Executive member of Japan Association of Corporate Executives and The British Chamber of Commerce in Japan.
Bob has over 25 years’ experience working in and advising technology, healthcare and financial services companies. He has engaged at every phase of corporate development, from formation to financing to operations to exiting, and has served in diverse roles from electrical engineer (Hughes Aircraft) to an associate at major law firms (Latham &Watkins, Morrison & Foerster) to general counsel for a series of technology and financial services companies to co-founder and managing director for a family of venture funds (Miramar Venture Partners).
Currently Bob provides legal services to investors through his boutique law firm Investor Counsel (www.investorcounsel.net), focused on the venture capital and private equity markets. His work encompasses fund formation, financing and operations, structuring and negotiating investments, mergers and acquisition, and purchaser representation. In addition, Bob continues to serve as a Managing Director for the legacy (fully invested) Miramar Venture Partners funds.
Bob also has served as an adjunct professor, teaching “Venture Capital Law” for one semester at the UC Irvine Law School and “Investing in New Ventures” for five semesters at USC’s Marshall School of Business, and writes about venture and M&A matters at http://holmen.ventures/. Bob received his B.S. in Electrical Engineering from Stanford University and his J.D. from UC Berkeley School of Law (Boalt Hall). Bob resides in Newport Beach with his wife and two daughters.